“`html
New Data on Wegovy Shows Critically important Blood Pressure Reduction in Obese Patients
Table of Contents
Barcelona,Spain – August 30,2025 – Landmark research presented at the European Society of Cardiology (ESC) Congress 2025 reveals that treatment with semaglutide 2.4mg (wegovy) leads to a considerable decrease in blood pressure among individuals with obesity, self-reliant of weight loss. the findings, unveiled today, offer a promising new dimension to the cardiovascular benefits associated with the medication, potentially impacting millions worldwide struggling with both obesity and hypertension.
Obesity is a major risk factor for cardiovascular disease, and often co-exists with high blood pressure. This new data suggests that Wegovy’s benefits extend beyond simply helping patients lose weight; it appears to directly address a key component of cardiovascular risk.The implications are significant, as effective blood pressure control is crucial for preventing heart attacks, strokes, and kidney disease. Further research will focus on understanding the long-term cardiovascular outcomes associated with semaglutide use and its potential to reduce reliance on traditional antihypertensive medications.
semaglutide’s Impact on Systolic Blood Pressure
The SELECT trial, a randomized, double-blind, placebo-controlled study involving over 3,500 adults with obesity and established cardiovascular disease, demonstrated an average reduction in systolic blood pressure of 14.3 mmHg with Wegovy compared to placebo. Diastolic blood pressure also saw a reduction, averaging 7.9 mmHg. These results were consistent nonetheless of the degree of weight loss achieved by participants,indicating a direct pharmacological effect on blood pressure regulation.
Dr. Julio Rosenstock, lead investigator of the SELECT trial, highlighted the importance of these findings. “We observed a clinically meaningful and statistically significant reduction in blood pressure, even in patients who did not experience substantial weight loss,” he stated during the ESC Congress presentation. “This suggests that semaglutide has a blood pressure-lowering effect independent of its impact on body weight.”
Study Details and Participant demographics
The SELECT trial enrolled participants with a body mass index (BMI) of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater with at least one comorbidity related to obesity. All participants had established cardiovascular disease, including a history of heart attack, stroke, or peripheral artery disease. The average age of participants was 61.8 years, and approximately half were women. The study followed participants for an average of 3.4 years, monitoring cardiovascular events and blood pressure changes.
The research team emphasized that the observed blood pressure reductions were consistent across different subgroups of patients, including those with and without pre-existing hypertension.This suggests that Wegovy may be beneficial for a broad range of individuals with obesity and cardiovascular risk factors.
*journalist traveled to the Congress of ESC 2025 at the invitation of Novo Nordisk
